The supplementary information contains 10 figures and 3 tables. Figures S1-S8 provide supplementary experimental results, describing the effect of olaparib on BRCA1 and RAD51 protein expression (Fig S1); FOXM1 isoform expression in ovarian carcinoma (Fig S2); Synergistic effects of thiostrepton and olaparib or carboplatin (Fig S3); Alterations in gene expression and pathways affected by thiostrepton (Fig S4); ENCODE data analysis of FOXM1 binding sites in HR genes (Fig S5); Effects of thiostrepton on HR genes'' expression and cell cycle (Fig S6); The effect of thiostrepton and olaparib or carboplatin on DNA damage (Fig S7); and the effect of thiostrepton on rucaparib sensitivity (Fig S8). Figure S9 and S10 contains results describing efficiency of thiostrepton encapsulation in micelles (Fig S9) and analysis of particle sizes of micelles (Fig S10). The supplement information also contains materials and methods associated with the supplementary figures. Finally, the document contains data describing the zeta potential of micelles (Table S1), qPCR primers'' sequences (Table S2) and the description of datasets from Connectivity Map project that was used in this study (Table S3).